Another blow to DMD community...In my opinion, it is imperative that combination therapy is the only way to tackle the problem.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-phase-3-study-investigational-gene
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not meet its primary endpoint of improvement in motor function among boys 4 to 7 years of age treated with the gene therapy compared to placebo. The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment (NSAA) at one year after treatment. Key secondary endpoints, including 10-meter run/walk velocity and time to rise from floor velocity, also did not show a significant difference between participants treated with fordadistrogene movaparvovec and placebo.
- Forums
- ASX - By Stock
- per-chart
Another blow to DMD community...In my opinion, it is imperative...
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.4¢ |
Change
-0.001(1.18%) |
Mkt cap ! $75.72M |
Open | High | Low | Value | Volume |
8.4¢ | 8.4¢ | 8.3¢ | $3.097K | 37.23K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 29206 | 8.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 118557 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 29206 | 0.083 |
2 | 30500 | 0.082 |
2 | 58100 | 0.081 |
2 | 160300 | 0.080 |
1 | 100000 | 0.079 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 118557 | 1 |
0.085 | 98557 | 2 |
0.086 | 6500 | 1 |
0.089 | 135000 | 2 |
0.090 | 386175 | 4 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |